The Global Guillain-Barre Syndrome Market size is expected to reach $852.2 billion by 2030, rising at a market growth of 4.6% CAGR during the forecast period.
North America, particularly the United States and Canada, has a robust healthcare infrastructure with high healthcare spending levels. Thus, the North America segment captured 36.2% revenue share in the market 2022. According to the Government of Canada, since 2014, approximately half of all cases of AFP that have been identified in Canada have been diagnosed with Guillain-Barré syndrome, and approximately twenty percent of those cases have been diagnosed with transverse myelitis.
GBS primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population ages, there’s a natural increase in the number of people at risk for GBS, which contributes to the rising prevalence of the condition.
Additionally, according to World Bank data, the World Bank Board of Directors approved US$50 million in new financing for Argentina to improve access to public healthcare services and ensure continued service for 6.5 million residents of the province of Buenos Aires without private health insurance. In conclusion, increasing global healthcare expenditures are driving the market’s growth.
However, the acute phase of GBS often requires hospitalization, intensive care, and specialized medical interventions such as plasma exchange and intravenous immunoglobulin (IVIG) therapy. These treatments can incur substantial healthcare costs, including hospital charges, medication expenses, and physician fees, placing financial strain on patients and healthcare systems. Thus, the high cost of treatment is impeding the market’s growth.
Drivers 
Restraints 
Opportunities 
Challenges Based on therapeutics, the market is bifurcated into intravenous immunoglobulin, plasma exchange, and others. In 2022, the intravenous immunoglobulin segment garnered 50.9% revenue share in the market. Intravenous immunoglobulin exerts its therapeutic effects through multiple mechanisms, including modulating immune responses.
On the basis of the route of administration, the market is segmented into parenteral and oral. In 2022, the oral segment attained a noteworthy revenue share in the market. Oral medications are increasingly utilized for early intervention in GBS cases with mild symptoms or as maintenance therapy following the acute phase of the disease.
Based on distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment registered 48.8% revenue share in the market. GBS management typically involves a multidisciplinary team of healthcare professionals, including neurologists, intensivists, physiotherapists, and pharmacists, working together to provide comprehensive patient care.
Free Valuable Insights: Global Guillain-Barre Syndrome Market size to reach USD 852.2 Million by 2030
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 28.2% revenue share in the market. The diagnostic rate of neurological illnesses, including GBS, has improved in the Asia-Pacific region due to increased public and healthcare professional knowledge.
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 602 Million |
| Market size forecast in 2030 | USD 852.2 Million |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 4.6% from 2023 to 2030 |
| Number of Pages | 233 |
| Number of Tables | 340 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Solution, Technology, Application, Vertical, Region |
| Country scope |
|
| Companies Included | F. Hoffmann-La Roche Ltd., Pfizer, Inc., PTC, Inc., AstraZeneca PLC, Novartis AG, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co., Inc., Bristol Myers Squibb Company |
By Therapeutics
By Route Of Administration
By Distribution Channel
By Geography
This Market size is expected to reach $852.2 billion by 2030.
Ongoing research and development are driving the Market in coming years, however, Potential complications and long-term disability related to GBS restraints the growth of the Market.
F. Hoffmann-La Roche Ltd., Pfizer, Inc., PTC, Inc., AstraZeneca PLC, Novartis AG, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co., Inc., Bristol Myers Squibb Company
The expected CAGR of this Market is 4.6% from 2023 to 2030.
The Parenteral segment is leading the Market by Route of Administration in 2022; thereby, achieving a market value of $524 million by 2030.
The North America region dominated the Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $295.7 million by 2030.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
